CDC42 and breast cancer: In another study, it was discovered that the REDOX/Fyn/c-CBL (RFC) pathway, which typically translates the slight increase in oxidation into the accelerated degradation of c-CBL target proteins, was inhibited by Cdc42 in basal-like breast cancer (BLBC) cells (Schmidt et al., 2006; Chen et al., 2013).